Metformin Oresund Pharma

Metformin Hydrochloride, the active ingredient in Metformin Oresund Pharma, is a biguanide presented as an oral tablet for oral use. It is used to lower blood glucose in adults with type 2 diabetes mellitus and works by decreasing hepatic glucose production while improving peripheral insulin sensitivity, helping to achieve glycemic control.

GNH USA supplies Metformin Oresund Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Oresund Pharma belongs to the biguanide class and is used to manage disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve overall glycemic control. - Impaired glucose tolerance (prediabetes): reduces the risk of progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome: helps correct insulin resistance, which can improve menstrual regularity and ovulation.

Metformin Oresund Pharma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: usually when combined with other glucose‑lowering agents. - Acute pancreatitis: inflammation of the pancreas. - Anemia: due to folate or B12 deficiency.

Before initiating Metformin Oresund Pharma, several safety considerations should be reviewed. - Renal function assessment: ensure adequate glomerular filtration rate before starting and periodically thereafter. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Lactic acidosis risk: discontinue if patient develops severe infection, hypoxia, or acute heart failure. - Vitamin B12 monitoring: check levels periodically during long‑term therapy. - Contraindicated in severe heart failure: avoid in patients with NYHA class III/IV. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Oresund Pharma can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol (excessive): enhances risk of lactic acidosis. - Rifampicin: reduces metformin exposure, potentially decreasing efficacy. - Digoxin: may increase digoxin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (thiazide): can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - Corticosteroids: may raise blood glucose, requiring dose adjustment. - Thyroid hormones: may alter metabolic rate, affecting glucose control.